Trends in antidiabetic drug utilization and expenditure in Denmark: A 22-year nationwide study

Medicin og biovidenskab

• Costs and Cost Analysis 9%
• Denmark 77%
• Dichlorodiphenyldichloroethane 9%
• Dipeptidyl-Peptidase IV Inhibitors 9%
• Drug Costs 8%
• Drug Utilization 100%
• Glucagon-Like Peptide-1 Receptor 9%
• Guidelines 4%
• Health Expenditures 74%
• Hypoglycemic Agents 69%
• Incidence 3%
• Insulin 9%
• Pharmaceutical Preparations 3%
• Sodium-Glucose Transporter 2 Inhibitors 10%
• Statistics 5%
• Symporters 9%
• Type 2 Diabetes Mellitus 5%